Q2FY25 Results: Sun Pharma on Monday reported financials for the second quarter ending September 30th, 2024. According to the pharma major’s exchange filing, the company’s net profit surged 28 percent on-year to Rs 3,040 crore.
During the quarter, the gross sales at Rs. 13264.2 crore, growth of 10.5 percent and the India formulation sales at Rs. 4265.2 crore which is up by 11 percent.
According to the company’s statement, US formulation sales at US$ 517 million, up 20.3 percent. India’s largest drugmaker’s consolidated revenue from operations too expanded 9 percent on-year to Rs 13,291 crore during July-September, fueled by double-digit growth across key markets, particularly the US.
The Global Specialty sales at US$ 286 million, up 19.2 percent and the emerging Markets formulation sales at US$ 293 million, up 3.2 percent. The company reported Rest of World formulation sales at US$ 199 million, down 3.5 percent.
Meanwhile,R&D investments stood at Rs. 792.9 crore compared to Rs. 773.4 crore for Q2FY24. The company’s EBITDA stood at Rs. 3939.0 crore (including other operating revenues), up 23.9 percent, with resulting EBITDA margin of 29.6 percent.
Also ReadSun Pharma and Philogen enter into exclusive agreement for commercialising anti-cancer immunotherapy
“Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercializing late stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market,” Dilip Shanghvi, Chairman and Managing Director of the Company said.
The company informed that its R&D efforts span across both specialty and generic businesses and they will continue to invest in building the pipeline for various markets including the US, Emerging Markets, RoW Markets and for India.
“Our specialty R&D pipeline includes 7 molecules undergoing clinical trials. We have a comprehensive product offering in the US market consisting of approved ANDAs for 538 products while filings for 105 ANDAs await US FDA approval, including 28 tentative approvals. Additionally, the portfolio includes 51 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 3 ANDA were filed and 1 ANDA approvals was received. Additionally, 1 NDA approval was received,” it added.
» Read More
